Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI
Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI
Active, not recruiting · NCT05845749 · Registry updated 2026-03-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Voxzogo for Growth Deficits in MPS IVA and VI | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Mucopolysaccharidosis Type IV A, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, connective tissue disorder, cutaneous mucinosis, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 4, mucopolysaccharidosis type 6 | Active, not recruiting | Phase 1 / Phase 2 | 2026-03-10 | NCT05845749 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of California, San Francisco | 637 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UCSF Benioff Children's Hospital Oakland | Oakland | United States | 85 |